Further Delineation of the De Santo Shinawi Syndrome Phenotype Using a Series of Individuals Carrying a Pathogenic Variant of the WAC Gene

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity Hospital, Clermont-Ferrand

About this trial

The aim of this retrospective, multicenter study would be to extend the phenotypic spectrum of DeSanto Shinawi Syndrome and improve the knowledge of its evolution. To this end, the investigators would like to issue a call for international collaboration in order to create a series of new genetically diagnosed patients, not yet described in previous publications, and with a larger number of individuals evaluated in a single study. One of the aims would be to establish a set of standardized clinical and paraclinical examinations to be carried out at diagnosis and for follow-up of affected patients. This would enable patients, their families and the caregivers involved to better anticipate future management.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Children and adults of any age.

Molecular diagnosis of a pathogenic (or likely pathogenic) variant involving the WAC gene (SNV, CNV, SV).

Disqualifiers

Patients with a molecular diagnosis of another VP (SNV) of a gene responsible for a neurodevelopmental disorder.

Patient having already participated in a DESSH study with published data.

No patient data available.

Trial population

Patients of any age with a molecular and clinical diagnosis of DeSanto-Shinawi Syndrome.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

50 Participants
are grouped into 1 trial group
Group A: Serie of patients with a molecular diagnosis of DeSanto-Shinawi Syndrome

Trial outcomes

Primary outcomes

1

Clinical knowledge

Morphologic description with photos (optional) at a specified date (front and side of the face, hands-feet : plant and palm) using HPO terms

Time frame
Through study completion, an average of 2 years
2

Clinical knowledge

Overall clinical examination and interrogatory at the last medical consultation (neurologic, cardiologic, gastroenterologic, pulmonary, urinary, global development, etc.) : data collected using a redcap form.

Time frame
Through study completion, an average of 2 years
3

Clinical knowledge

Height, weight and head circumferance at birth and at last visit

Time frame
Through study completion, an average of 2 years
4

Paraclinical knowledge

Any psychometric scale performed during lifetime : Language delay, Motor delay, ADHD, IQ, ASD

Time frame
Through study completion, an average of 2 years

Secondary outcomes

1

Recurrence of clinical signs

Inventory the clinical signs of the syndrome described to date and mesure concordance or not

Time frame
Through study completion, an average of 2 years
2

Standardized examinations

Using concordance of signs, mesure the clinical and paraclinical necessary at diagnosis

Time frame
Through study completion, an average of 2 years
3

Management & Follow-up

Using concordance of signs at different ages, establish appropriate management and follow-up.

Time frame
Through study completion, an average of 2 years
4

Genotype phenotype correlation

Compare the phenotype of DESSH patients with pathogenic point variation in the WAC gene and those with microdeletion involving the WAC gene

Time frame
Through study completion, an average of 2 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.